Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease, National Clinical Research Center for Dermatologic and Immunologic Diseases(NCRC-DID), Beijing, China.
Eight-year program of Clinical Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Front Immunol. 2022 Jul 28;13:913424. doi: 10.3389/fimmu.2022.913424. eCollection 2022.
Allergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose. Seasonal ARC (SARC) is usually induced by seasonal allergens and often occurs at specific times during the year. Traditional treatments of SARC include nasal corticosteroids, antihistamines, and mast cell membrane stabilizers. Biological agents such as omalizumab have also been proved effective in the treatment of SARC.
We aim to certify the preventative efficacy of omalizumab for SARC and explore its influence factors.
Medical records of 64 SARC patients were retrospectively analyzed, and generalized linear models were used to analyze influence factors of efficacy of omalizumab.
Compared with forepassed pollen season without omalizumab treatment, the combined symptom and medication score (CSMS) of ARC with pre-seasonal omalizumab was significantly lower (with omalizumab: 0.67[0.00,1.83], without omalizumab: 4.00[2.83,4.96], p<0.001, max score=6). Subgroup analysis was conducted to explore the influence factor of preventative efficacy of omalizumab. The CSMS with omalizumab treatment were not significantly different among different age, gender, dosage, number of injections, and injection date subgroups (p>0.05).
Pre-seasonal omalizumab treatment could significantly relieve SARC related symptoms and reduce medication use. This preventative efficacy would not be influenced by the dosage and number of injections of omalizumab. A single dose of 150mg omalizumab could achieve a satisfactory outcome.
变应性鼻结膜炎（AR）是一种过敏疾病，其特征是结膜和鼻部症状，如结膜水肿和充血、流涕、打喷嚏和鼻塞。季节性 AR（SARC）通常由季节性过敏原引起，通常在一年中的特定时间发生。SARC 的传统治疗包括鼻用皮质类固醇、抗组胺药和肥大细胞膜稳定剂。奥马珠单抗等生物制剂也已被证明对 SARC 的治疗有效。
我们旨在证明奥马珠单抗预防 SARC 的疗效，并探讨其影响因素。
回顾性分析 64 例 SARC 患者的病历，采用广义线性模型分析奥马珠单抗疗效的影响因素。
与未用奥马珠单抗治疗的前一个花粉季节相比，季节性前使用奥马珠单抗治疗的 ARC 的综合症状和药物评分（CSMS）显著降低（有奥马珠单抗：0.67[0.00,1.83]，无奥马珠单抗：4.00[2.83,4.96]，p<0.001，最大得分=6）。进行亚组分析以探讨奥马珠单抗预防疗效的影响因素。在不同年龄、性别、剂量、注射次数和注射日期亚组中，奥马珠单抗治疗的 CSMS 无显著差异（p>0.05）。
季节性前奥马珠单抗治疗可显著缓解 SARC 相关症状并减少用药。这种预防疗效不受奥马珠单抗剂量和注射次数的影响。单次注射 150mg 奥马珠单抗即可获得满意的效果。
